DOJ Announces First Health Care Company Declination - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

DOJ Announces First Health Care Company Declination

Campus Eye avoided prosecution after voluntarily disclosing misconduct, cooperating with investigators, and remediating the wrongdoing.

  • By

  • Kathryn Wighton

  • August 13, 2026

  • 2 min

Share

Clinical Scorecard: DOJ Announces First Health Care Company Declination

At a Glance

CategoryDetail
ConditionClinical topic addressed by the source article: DOJ Announces First Health Care Company Declination
Key MechanismsMechanisms or clinical associations described in the source article.
Target PopulationHealth care companies and executives involved in misconduct related to health care fraud.
Care SettingCare setting described in the source article.

Key Highlights

  • DOJ declined to prosecute Campus Eye Management Holdings LLC after voluntary disclosure and cooperation.
  • Campus Eye agreed to repay $1 million to victims as part of the resolution.
  • E. Bruce DiDonato indicted on multiple counts related to health care fraud and kickback schemes.
  • The declination reflects the DOJ's Corporate Enforcement and Voluntary Self-Disclosure Policy.
  • If convicted, DiDonato faces a potential maximum of 45 years in prison.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Clinical Best Practices

          • Voluntary disclosure of misconduct can lead to declination of prosecution.
          • Cooperation with investigations is critical for favorable outcomes.

          Related Resources & Content

          Original Source(s)

          DOJ Announces First Health Care Company Declination

          • by Kathryn Wighton

          • August 13, 2026

          Related Content

          Artificial Tears Improve Tear Stability

          Preservative-free carboxymethyl cellulose drops modestly increased tear break-up time and produced small corneal epithelial changes in screen-exposed patients.

          Could Red-Light Therapy Change Myopia Care? 

          Across 28 trials, pediatric patients receiving therapy had less myopia progression over 12 months, though long-term risks remain under study.

          FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia

          Deseyne delivers smooth, continuous focus across near, intermediate, and distance vision, which is enabled by Cataltheia’s patented hyper-refractive central zone, engineered to precisely redirect light in a controlled manner.